ASND250117C160000
- 5.80
- 0.000.00%
Ascendis Pharma A/S Newsroom
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $220
Ascendis Pharma's YORVIPATH Now Commercially Available In The U.S. For The Treatment Of Hypoparathyroidism In Adults
Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $194
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $167 to $211
Express News | Ascendis Pharma A/S : Jefferies Raises Target Price to $194 From $191
Ascendis Pharma (ASND) Gets a Buy From Stifel Nicolaus
Ascendis Pharma Presents New InsiGHTS Trial Of TransCon HGH In Turner Syndrome Achieved Primary Objective At Week 26; Results For All Three TransCon HGH Starting Dose Cohorts, In First Clinical Trial Of An Indication Outside Of Growth Hormone...
Ascensis Pharma Says FDA Will Review Application for Adult Treatment of Growth Hormone Deficiency
Express News | Ascendis Pharma Announces FDA Accepts Co's Supplemental Biologics License Application For TransCon HGH For The Treatment Of Adults With Growth Hormone Deficiency
European Equities Traded in the US as American Depositary Edge Higher in Wednesday Trading
Orsini Chosen by Ascendis to Distribute Treatment for Rare Endocrine Disorder in the U.S.
Peering Into Ascendis Pharma's Recent Short Interest
JPMorgan Updates Its U.S. Analyst Focus List – Adds TPR, ALRM, REG
JPMorgan's 'Analyst Focus List' – Growth, Income, Value, Short Ideas
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Express News | Ascendis Pharma A/S : Citigroup Cuts Target Price to $200 From $207
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $153 to $207
Express News | Acendis Pharma Shares Are Trading Higher After Stifel Maintained a Buy Rating on the Stock and Raised Its Price Target From $200 to $207
European Equities Traded in the US as American Depositary Drop in Friday Trading, Down 2.8% for Week
Ascendis Pharma Price Target Maintained With a $170.00/Share by Cantor Fitzgerald